It is now clear that the predominant metabolic effect of sulfonylurea compounds is to release insulin from pancreatic beta cells. In addition, assays by Yalow, Black, Villazon and Berson (1) of insulin concentrations in peripheral blood indicate that the secretory potency of sulfonylureas is substantially weaker than that of glucose. More quantitative comparison of insulin-releasing activities of individual substances, however, requires knowledge of both the concentration of insulin in pancreatic venous blood, and the latter's rate of flow. A suitable closed circuit enabling these measurements was devised by Metz (2), who determined total insulin outflow from the pancreaticoduodenal vein draining the right pancreatic limb in dogs during glucose infusion into the femoral vein. The latter technic was employed in the present study to determine total secretion of insulin activity from a segment of dog pancreas for 30 minutes after glucose or a hypoglycemia-inducing agent was injected into a peripheral vein. Although glucose and three sulfonylurea compounds all promptly initiated release of insulin, glucose was by far the most potent insulogenic substance. In contrast, neither salicylate nor indole-3-acetic acid altered the rate of insulin secretion.
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METHODS
Mongrel dogs of either sex, weighing between 10 and 15 kg, were used in all experiments. During a quarantine period of 14 days, animals were metabolically stabilized on a daily ration of meat and Purina laboratory chow, which provided approximately 60 g protein, 20 g fat and 90 g carbohydrate. In early experiments, intact dogs were used after a 24-hour fasting period. How-* This work was supported in part by Grant A-4708 from the United States Public Health Service, Bethesda, Md. This paper was presented in part at the Southern Society for Clinical Research, New Orleans, La., January 23, 1960. ever, it shortly became evident that the normal hyperglycemic response to anesthetic and surgical trauma caused premature discharge of insulin, which masked insulin-releasing activity of all agents except glucose itself (Table I) . Accordingly, animals were starved and phlorhizinized for 3 days preoperatively, to deplete hepatic glycogen stores maximally and lower peripheral blood glucose to hypoglycemic levels. In dogs weighing 13 kg or less initially, 5 ml of a 40 per cent solution of phlorhizin in propylene glycol was injected subcutaneously approximately 64, 48, 40, 24, and 16 hours before operation; the total phlorhizin dosage was 10 g. Dogs weighing above 13 kg were given 6 ml per dose, and total dosage was 12 g. All animals also received two injections of 1: 500 epinephrine-in-oil, 1 ml intramuscularly at 40 and 16 hours before surgery. Animals were anesthetized with pentobarbital sodium (Nembutal), 25 mg per kg intravenously, and laparotomized by midline incision. The posterior surface of the right pancreatic limb was exposed by delivering the free loop of the duodenum into the wound and reflecting it to the left. The cranial pancreaticoduodenal vein, draining all of the right limb of the pancreas except its distal tip, was usually visible and accessible with variable ease beneath the surface of the gland. The vessel was cannulated in retrograde direction (upstream against blood flow) about 2 cm distal to its confluence with the portal vein, using a plastic catheter of large bore (PE 240, OD 0.095 inch) to allow free flow of effluent. The vein was ligated proximal to the point of cannulation to prevent backflow of blood from the portal vein. Immediately before cannulation, the dog was heparinized with 1,500 U per kg of body weight. After cannulation, the entire venous outflow was collected uninterruptedly in a baseline (control) aliquot during the first 10 minutes; and then in three postinjection collections, each of 10 minutes' duration. Total volume and hematocrit were determined on all aliquots. In some animals an additional femoral venous aliquot was obtained before injection, and 10 minutes thereafter, for estimation of insulin activity in peripheral plasma. At the end of the baseline collection, the test substance was inj ected into a femoral vein.
Eight dogs received 15 g of glucose (30 ml (3) . Aliquots of pancreaticoduodenal and femoral venous blood were centrifuged immediately, and the separated plasma was refrigerated at 70 C. All samples were assayed within a week of procurement, and all specimens from an animal were assayed simultaneously. Plasma insulin activity was assayed by determining the glucose uptake from 2 ml of undiluted plasma by isolated rat hemidiaphragm, adhering strictly to the technic described by Vallance-Owen and Hurlock (4) . Male Wistar rats, weighing between 90 and 130 g, were used after food was withheld for 18 to hours at 1100 C, cooled, and weighed. Glucose uptake was expressed as micrograms per 10 mg of dried diaphragm. "Net glucose uptake" signified total glucose uptake from a sample minus baseline glucose uptake by diaphragm incubated in GBSS alone. Technical limitations prevented simultaneous performance of both a dose-response curve and all samples from a single experiment. Accordingly, at intervals of 2 to 4 weeks a dose-response curve was done, by determining net glucose uptake from triplicate 2-ml aliquots of GBSS containing 10, 100, and 1,000 AU of insulin per ml, respectively. The mean of 24 individual dose-response curves yielded the standard dose-response curve ( Figure  1 ) from which experimental values for net glucose uptake were converted into microunits of "effective insulin concentration" per milliliter of plasma. Conversion values between 1 and 10 AU per ml of plasma were estimated by extrapolation. The few glucose uptakes exceeding the equivalent for an insulin concentration of 1,000 /AU per ml of GBSS (Table II) were included in calculations as the latter value.
Pancreaticoduodenal venous plasma flow (PP flow) was derived by multiplying the rate of pancreaticoduodenal venous blood flow (PB flow) by the "plasmacrit": PB flow (ml/min) X (100 -hematocrit)
100
= PP flow (ml/min) [1] The concentration of insulin activity in pancreaticoduodenal venous plasma (PIA), multiplied by pancreaticoduodenal venous plasma flow, yielded outflow rate of plasma insulin activity (PIA flow):
PIA (MU/ml) X PP flow (ml/min) = PIA flow (MU/min) [2] NO NO0 v. All 24 individual dose-response curves, and hence the mean curve derived from them, were curvilinear when plotted on the usual semilogarithmic coordinates. However, as Vallance-Owen, Hurlock and Please (6) originally demonstrated and validated statistically, and as Wright (7) and Gundersen (8) B. Secretory rates of insulin activity in pancreaticoduodenal venous plasma after administration of test substances (Table II, Figures 2 and 3)
1. After glucose. At the end of the 5-minute injection of 15 g of glucose, peripheral blood glucose level (mean ± SEM) was 417 ± 21 mg per 100 ml, and 25 minutes later it had fallen to 236 + 12 mg per 100 ml. Glucose evoked a prompt and prodigious rise in pancreatic outflow of insulin activity, with only a slight decrease during the 30 minutes of observation. The increased secretion was due to greatly enhanced titers of insulin activity in pancreatic venous blood, since neither pancreatic blood flow nor hematocrit changed significantly. Respective concentrations of effective insulin activity were <.001 <.001 <.WH <.01 <.01 <.05 <.0S <.1 <.0S5
. All of these increases above baseline exceeded p < 0.001 level of significance. 2. After sulfonylurea compounds. The effects of tolbutamide, chlorpropamide, and metahexamide on release of insulin activity resembled that of glucose qualitatively, but not quantitatively. As a group, they sharply augmented insulin activity in pancreatic venous blood during the first 10 minutes, although maximal secretory rates in individual experiments occurred in any of the three collection intervals. The magnitude of response to these agents, however, was only a fraction of that following glucose (Figure 2 at 333 ± 110 fxU per minute (p < 0.2) during the last period. All increases of insulin flow rates above baseline levels were due to enhanced concentrations of insulin activity in pancreaticoduodenal venous plasma, and not to increased plasma flow rates.
3. After salicylate and indole-3-acetic acid. Neither sodium salicylate nor sodium indole-3-acetate stimulated release of insulin activity (Figure 3 4 . After sulfadiazine and saline. Similarly, administration of sodium sulfadiazine or sodium chloride as control substances elicited no change in preinjection outflow rates of insulin activity (Figure 3 ).
C. Comparison of insulagenic potencies
The last column in Table II shows the mean increase of insulin outflow rate above baseline value during the entire 30-minute interval. After glucose administration, the average increase in pancreatic venous insulin activity was 2,968 ± 567 ,uU per minute (100.0 +19.1 per cent). The average increase after tolbutamide was 294 + 70 MAU per minute (9.9 + 2.4 per cent).. After chlorpropamide the mean increase was 553 ± 188 uU per minute (18.6 + 6.4 per cent), and after metahexamide the corresponding mean enhancement was 347 ± 87 puU per minute (11.7 ± 2.9 per cent). All of these increments were significant at p < 0.02 or better. In contrast, after salicylate the increase above baseline value was only 57 ± 42 uU per minute (1.9 ± 1.4 per cent), and after indole-3-acetic acid it was 52 ± 38 uU per minute (1.8 ± 1.3 per cent). insulin activity, or the effective plasma-insulin concentration, i.e., the sum of insulin and its synergists, if any, on the one hand and its antagonists on the other" (9) . Nevertheless, in the present study, the conclusion seems reasonable that the flow rates of insulin activity in pancreaticoduodenal venous effluent truly reflected the rate of insulin secretion by beta cells. The isolated rat diaphragm is sufficiently specific for assaying insulin activity that it does not detect "insulin activity" in blood from totally depancreatized animals (10, 11) , in contrast to the more sensitive but apparently less specific rat epididymal fat pad (12, 13) . Similarly, by Vallance-Owen's method, two totally pancreatectomized patients exhibited no circulating insulin activity either before or after ingesting 100 g of glucose (Table VI) specific increase of glucose uptake by rat diaphragm.
At the same time, experimental values for concentrations and flow rates of insulin activity denoted only relative quantitation of insulin secretion. Since the cranial pancreaticoduodenal vein in the dog drains a segment of gland containing about 30 per cent of total islet cell volume (14) , only a fraction of total insulin secretion was measured. A more critical dissuader from misinterpreting relative values as absolute, however, is the fact that reported "normal" values for insulin content of blood differ widely (15) . This discrepancy even exists between workers using undiluted plasma and rat diaphragm as assay tissue, but varying otherwise in method. Metz (2) found baseline insulin activity in pancreaticoduodenal venous blood of dogs to vary from 10 to 31 mU per 100 ml of plasma (100 to 310 /tU per ml) at blood glucose levels between 37 and 86 mg per 100 ml, with enhancement to values of 330 and 570 mU per 100 ml plasma (3,300 and 5,700 FLU per ml) when blood glucose was 300 mg per 100 ml. These absolute values, about ten times greater than those recorded under similar experimental conditions in the present study, are largely due to his ten times less sensitive doseresponse curve, since actual net glucose uptakes from plasma were essentially the same in both laboratories. In contrast, the specific immunoassay of Yalow and Berson (16) yielded values for actual insulin concentrations in human plasma very similar to those for biologic "insulin activity" found by Vallance-Owen and co-workers (4, 6), Wright (7), .nd Seltzer and Sluith (17) . These comparable results by two entirely different pro-cedures suggest that absolute concentrations of circulating insulin are, in fact, low rather than high.
Even in relative terms, however, the parameter of insulin-releasing activity enabled sharp qualitative and quantitative classification of test substances. Glucose and all three sulfonylureas stimulated prompt discharge of insulin, whereas salicylate and indole-3-acetic acid had no effect. The insulogenic potency of glucose far exceeded that of sulfonylureas. Rapidly induced hyperglycemia evoked a tremendous outpouring of insulin, whose secretory rate promptly reached a maximal level which was essentially sustained for 30 minutes. The slight drop during the last period may have reflected the waning glycemic stimulus as blood glucose level fell rapidly, since Metz (18) found that glucose infused at mounting rates for 45 minutes continued to elicit proportional increase of insulin secretion. In contrast to the massive response to glucose, the insulin-releasing potency of all three sulfonylurea compounds was much smaller, both in magnitude and duration. Mean outflow rates for the nine periods of observation never exceeded 20 per cent of the maximal rate for glucose (Table II and Figure 2 ). Moreover, in Figure 4 are compared respective mean increases of insulin secretion during the entire 30 minutes after injection of glucose and sulfonylureas. Considering enhancement by glucose as 100 per cent, corresponding insulogenic potencies were 9.9 per cent for tolbutamide, 18.6 per cent for chlorpropamide, and 11.7 per cent for metahexamide. Although blood levels of sulfonylurea were not measured, maintenance of effective concentrations was assured by the known half-life disappearance rates for tolbutamide, chlorpropamide, and metahexamide of 4.6, 35, and 19 hours, respectively (19, 20) .
The insulogenic omnipotence of glucose has previously been intimated in published clinical observations. One hour after giving 50 g of glucose orally, Vallance-Owen and associates found an increment in plasma insulin activity of 333 utU per ml in normal subjects (4), and 219 tU per ml in maturity-onset diabetics (6). Two and one-half hours after similar individuals took 2 g of tolbutamide by mouth, the average increase of plasma insulin activity was 114 /U per ml in normal subjects, and 130 /U per ml in adult dia- betics (21) . Similarly, both in normal subjects and in untreated mild diabetics, Yalow and coworkers (1) found greater enhancement of plasma insulin levels after glucose than after tolbutamide. In nondiabetics the average increase after glucose was 119 uU per ml, compared to only 28 IU per ml after tolbutamide; in diabetic patients corresponding mean increases were 132 ,tU per ml after glucose and 52 uU per ml after tolbutamide. In these clinical studies, the full insulogenic superiority of glucose over sulfonylurea compounds was probably masked for several reasons. In addition to significant hepatic binding of intra-portalvenous insulin during its first traverse of the liver (22) , and dilution of the remainder upon entering the post-hepatic circulation, isolated values of insulin concentration tend to obscure the sustained nature of the glycemic stimulus compared to the transient one invoked by sulfonylureas.
An opposite interpretation might be that the observed insulogenic superiority of glucose was an artifactual sequela of the chronic hypoglycemia induced in experimental animals. The hypoglycemic state is combated by the counterregulatory release of epinephrine (23) , adrenocorticosteroids (24) , and glucagon (25) . Epinephrine and cortisol strongly inhibit the enhancing effect of insulin on glucose uptake by rat diaphragm (26, 27) , wherefore their presence in excess in test plasmas could have blunted the full betacytotropic effects of sulfonylurea agents. However, even in animals whose hypoglycemia was obliterated by glu-cose administration, it is unlikely that preinjection plasma levels of epinephrine or cortisol changed significantly during the next 30 minutes, since epinephrine-in-oil had been used in preparing all animals, and circulating cortisol titers are known to be markedly elevated during surgical trauma per se (28) .
The implication that the physiological stimulus represented by a rising blood sugar level can stimulate normal beta cells maximally and indefinitely, suggests that glucose and sulfonylureas impinge differently upon the beta cell. Glucose appears to be truly "insulogenic" in that it not only triggers release of stored insulin granules, but also engenders formation and secretion of new insulin in proportion to the concentration of glucose in pancreatic arterial blood. In contrast, sulfonylurea compounds seem merely capable of "solubilizing" preformed, stored insulin and enabling it to be rapidly discharged. Thereafter, so long as effective sulfonylurea blood levels persist, spontaneously synthesized insulin is promptly secreted regardless of arterial glucose concentration. Volk and Lazarus (29) demonstrated totally degranulated beta cells during chronic tolbutamide-induced hypoglycemia in rabbits and dogs. Moreover, after 9 months of daily tolbutamide administration to rats, Baender (30) found that several days after stopping the drug, normal beta cell granulation had been restored. Of similar significance may be the repeated clinical observation that, although sulfonylureas normalize glucose levels in optimally responsive ketoacidosisresistant diabetics, the oral glucose tolerance test itself frequently shows little improvement (31, 32) . This apparent paradox is actually a predictable sequela, if pancreatic islets continuously bathed in a sulfonylurea solution cannot conserve a depot of insulin to release upon hyperglycemic demand.
Recent clinical trials with salicylate in diabetic patients have shown that its ability to lower blood sugar is equal to that of sulfonylurea and phenethylbiguanide compounds. Unfortunately, normalization of fasting blood glucose in maturityonset diabetics was achieved by Reid and MacDougall (33) at blood levels of salicylate (above 40 mg per 100 ml) too toxic to encourage its therapeutic use. However, when this agent was selectively used only in mild adult diabetics whose blood glucose was optimally responsive to tolbutamide, fasting normoglycemia was indefinitely maintained at well tolerated blood levels between 25 and 35 mg per 100 ml (34) . In the present study, failure of the latter concentrations to manifest betacytotropic activity confirms the exclusively extrapancreatic action of salicylate. Manchester, Randle and Smith (35) showed significant augmentation of glucose uptake by rat diaphragm when salicylate was added in vitro, a finding verified in Table IV (37) .
The hypoglycemia-inducing property of indole-3-acetic acid was discovered by Mirsky, Diengott and Perisutti (38) during studies elucidating its ability to inhibit insulinase activity. Clinical titration in diabetic patients revealed this physiological end-product of tryptophan metabolism to be fully as effective as tolbutamide in reducing fasting hyperglycemia (39) . Because indole-3-acetic acid is also a powerful plant growth hormone, it might have possessed an "insulotropic" action similar to that by which animal growth hormone stimulates anatomical and functional hypertrophy of beta cells (40) . However, not only was the agent devoid of betacytotropic activity, but its addition to the in vitro assay system did not increase glucose uptake by rat diaphragm. In addition, even profound hypoglycemic responses of elderly diabetics to the substance were not accompanied by increased plasma insulin activity (39) . In a negative sense, therefore, these findings support the conclusion of Mirsky and coworkers that indole-3-acetic acid preponderantly blocks destruction of insulin by insulinase.
Finally, the apparent failure of proved hypoglycemia-inducing agents to cause further lowering of blood sugar was an expected sequela of the experimental procedure. Preliminary efforts in intact dogs had consistently shown that the necessarily extensive surgical manipulations caused peripheral hyperglycemia, which not only evoked premature insulin secretion but also canceled the glucose-depressing activity of the agent under scrutiny. When the animal was depleted of glycogen by starvation, phlorhizin, and epinephrine to prevent otherwise uncontrollable hyperglycemic interference, the normal hypoglycemic response to the test substance was also blunted.
SUMMARY
Respective betacytotropic activities of glucose, sulfonylurea compounds, salicylate, and indole-3-acetic acid were semiquantitatively compared by measuring the effect of each agent on the outflow rate of insulin activity in pancreaticoduodenal venous blood of phlorhizinized dogs.
Glucose and three sulfonylureas (tolbutamide, chlorpropamide, and metahexamide) all promptly enhanced concentration of insulin activity in the pancreatic venous effluent. However, whereas the response to glucose was both intense in magnitude and sustained, insulin release by sulfonylureas was only moderate in degree and transient in duration. Mean enhancement of insulin secretion by glucose was five to ten times the output after sulfonylurea compounds. Neither salicylate nor indole-3-acetic acid stimulated pancreatic release of insulin activity.
The data suggest that: 1) both glucose and sulfonylurea compounds cause prompt release of insulin from pancreatic beta cells; 2) the betacytotropic activity of glucose is far more potent than that of sulfonylureas; 3) glucose is truly insulogenic; i.e., capable of engendering formation of new insulin, whereas sulfonylureas seem only able to release preformed stores of insulin; and 4) salicylate and indole-3-acetic acid cause peripheral hypoglycemia via extrapancreatic mechanisms.
